Immunogenicity and Safety of Adacel Polio Vaccine

Inclusion Criteria: * Aged 6 to 8 years on the day of inclusion * Informed consent form signed by the parent(s) or another legally acceptable representative * Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures * Written documentation of complete primary series and fourth dose of diphtheria, tetanus, pertussis (DTP) and Polio vaccines * Parent(s)/legal representative present or fully completed pre-inclusion medical questionnaire. Exclusion Criteria: * Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination * Planned participation in another clinical trial during the present trial period * Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy * Known systemic hypersensitivity to any of the vaccine components (or residues carried over from manufacture, such as formaldehyde, glutaraldehyde, streptomycin, neomycin and polymyxin B ) or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances with specific focus on subjects who had, after previous administration of DTP vaccine, one of the pre-listed adverse events. * Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator * Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy * Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response * Receipt of any vaccine in the 4 weeks preceding the trial vaccination * Planned receipt of any vaccine in the 4 weeks following the trial vaccination * Known Human Immunodeficiency Virus (HIV), Hepatitis B surface (HBs) antigen, or Hepatitis C seropositivity * History of diphtheria and/or tetanus and/or pertussis and/or poliomyelitis infection (confirmed either clinically, serologically or microbiologically) * Previous fifth vaccination against diphtheria and/or tetanus and/or pertussis and/or poliomyelitis diseases with either the trial vaccine or another vaccine * Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular (IM) vaccination * Subject at high risk for diphtheria and/or tetanus and/or pertussis and/or poliomyelitis infection during the trial * Received oral or injected antibiotic therapy within the 72 hours prior to any blood draw * Febrile illness (temperature ≥ 37.5°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment